Tamara Y. Milder MMed (ClinEpi), Jialing Lin PhD, Sallie-Anne Pearson PhD, Juliana de Oliveira Costa PhD, Brendon L. Neuen PhD, Carol Pollock PhD, Min Jun PhD, Jerry R. Greenfield PhD, Richard O. Day MD, Sophie L. Stocker PhD, David Brieger PhD, Michael O. Falster PhD
{"title":"2 型糖尿病患者因心力衰竭住院后停用 SGLT2i:值得关注吗?","authors":"Tamara Y. Milder MMed (ClinEpi), Jialing Lin PhD, Sallie-Anne Pearson PhD, Juliana de Oliveira Costa PhD, Brendon L. Neuen PhD, Carol Pollock PhD, Min Jun PhD, Jerry R. Greenfield PhD, Richard O. Day MD, Sophie L. Stocker PhD, David Brieger PhD, Michael O. Falster PhD","doi":"10.1111/dom.16061","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 2","pages":"997-1000"},"PeriodicalIF":5.7000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?\",\"authors\":\"Tamara Y. Milder MMed (ClinEpi), Jialing Lin PhD, Sallie-Anne Pearson PhD, Juliana de Oliveira Costa PhD, Brendon L. Neuen PhD, Carol Pollock PhD, Min Jun PhD, Jerry R. Greenfield PhD, Richard O. Day MD, Sophie L. Stocker PhD, David Brieger PhD, Michael O. Falster PhD\",\"doi\":\"10.1111/dom.16061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"27 2\",\"pages\":\"997-1000\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16061\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.